466 results on '"Ribaudo, Heather J"'
Search Results
52. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)
53. Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV
54. Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk
55. Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation
56. Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis
57. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).
58. Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission
59. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
60. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202
61. Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-infected Women in Botswana
62. Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV.
63. Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk
64. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT
65. Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
66. Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV-1 Response to Antiretroviral Therapy
67. Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure
68. Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095
69. Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics
70. Efavirenz-Based Regimens in Treatment-Naive Patients with a Range of Pretreatment HIV-1 RNA Levels and CD4 Cell Counts
71. Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects
72. Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving Either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s
73. COVID-19 Vaccination Rates in a Global HIV Cohort
74. Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir
75. A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease
76. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial
77. Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial
78. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS clinical trials group study A5095)
79. Three- versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial
80. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
81. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388
82. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
83. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection
84. Quality of Life Following Surgery for Intracranial Meningiomas at Brigham and Women's Hosipital: A Study of 164 Patients Using a Modification of the Functional Assessment of Cancer Therapy–brain Questionnaire
85. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
86. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure
87. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis
88. Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases
89. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators
90. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
91. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE
92. Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
93. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
94. A Comparison of Three Initial Antiretroviral AIDS Regimens
95. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
96. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
97. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
98. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
99. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial
100. Cost-effectiveness evaluation to inform clinical trial design
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.